Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
Authors
Keywords
-
Journal
LANCET
Volume 398, Issue 10317, Pages 2160-2172
Publisher
Elsevier BV
Online
2021-11-17
DOI
10.1016/s0140-6736(21)01751-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data
- (2021) Sean Wharton et al. INTERNATIONAL JOURNAL OF OBESITY
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity
- (2021) Thomas A. Wadden et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
- (2021) John P.H. Wilding et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity
- (2021) Domenica Rubino et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial
- (2021) Lone B Enebo et al. LANCET
- Development of Cagrilintide, a Long-Acting Amylin Analogue
- (2021) Thomas Kruse et al. JOURNAL OF MEDICINAL CHEMISTRY
- Central control of energy balance by amylin and calcitonin receptor agonists and their potential for treatment of metabolic diseases
- (2020) Hannah Louise Zakariassen et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- Obesity in adults: a clinical practice guideline
- (2020) Sean Wharton et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- Amylin brain circuitry
- (2020) Lavinia Boccia et al. PEPTIDES
- Cardiovascular and Metabolic Heterogeneity of Obesity
- (2018) Ian J. Neeland et al. CIRCULATION
- Progress and challenges in anti-obesity pharmacotherapy
- (2018) Daniel H Bessesen et al. Lancet Diabetes & Endocrinology
- Amylin – Its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity
- (2018) Christina Neuner Boyle et al. Molecular Metabolism
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY
- (2016) W. Timothy Garvey et al. Endocrine Practice
- Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events
- (2016) Rohan Khera et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes
- (2011) R. R. Wing et al. DIABETES CARE
- Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial
- (2011) Kishore M Gadde et al. LANCET
- Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- (2010) Frank L Greenway et al. LANCET
- Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity
- (2008) S. R. Smith et al. DIABETES CARE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started